$4.88
+0.37 (+8.20%)
Open$4.58
Previous Close$4.51
Day High$4.92
Day Low$4.58
52W High$7.45
52W Low$4.53
Volume—
Avg Volume250.7K
Market Cap35.19M
P/E Ratio—
EPS$-1.28
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+44.3% upside
Current
$4.88
$4.88
Target
$7.04
$7.04
$5.84
$7.04 avg
$9.41
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 4.92M | 4.60M | 4.74M |
| Net Income | -168,115 | -132,709 | -155,737 |
| Profit Margin | -3.4% | -2.9% | -3.3% |
| EBITDA | -202,888 | -214,542 | -195,381 |
| Free Cash Flow | -99,394 | -85,981 | -141,773 |
| Rev Growth | -1.4% | -8.7% | +11.4% |
| Debt/Equity | 0.90 | 0.85 | 0.90 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |